Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”: [Annals of Oncology 32 (2021) 950-953]

J. J. Gao, D. Krol, P. Narayan, F. Cardoso, M. M. Regan, M. P. Goetz, S. A. Hurvitz, L. Mauro, C. Hodgdon, C. P. Miller, B. Booth, E. Bloomquist, G. Ison, C. Osgood, V. Bhatnagar, L. Fashoyin-Aje, R. Pazdur, L. Amiri-Kordestani, J. A. Beaver

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret the original funding statement in this article was incorrect. The funding statement should read as follows: “This work was supported by the Mayo Clinic Breast Cancer Specialized Program of Research Excellence Grant (P50CA 116201). Dr. Goetz is the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.” The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)356
Number of pages1
JournalAnnals of Oncology
Volume33
Issue number3
DOIs
StatePublished - Mar 2022

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”: [Annals of Oncology 32 (2021) 950-953]'. Together they form a unique fingerprint.

Cite this